1. Home
  2. EBC vs ADPT Comparison

EBC vs ADPT Comparison

Compare EBC & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Eastern Bankshares Inc.

EBC

Eastern Bankshares Inc.

HOLD

Current Price

$22.36

Market Cap

4.2B

Sector

Finance

ML Signal

HOLD

Logo Adaptive Biotechnologies Corporation

ADPT

Adaptive Biotechnologies Corporation

HOLD

Current Price

$26.33

Market Cap

4.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EBC
ADPT
Founded
1818
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Accident &Health Insurance
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.2B
4.1B
IPO Year
2020
2019

Fundamental Metrics

Financial Performance
Metric
EBC
ADPT
Price
$22.36
$26.33
Analyst Decision
Buy
Strong Buy
Analyst Count
5
9
Target Price
$22.70
$17.78
AVG Volume (30 Days)
2.5M
2.4M
Earning Date
04-23-2026
05-05-2026
Dividend Yield
3.02%
N/A
EPS Growth
N/A
63.89
EPS
0.77
N/A
Revenue
$134,091,000.00
$276,976,000.00
Revenue This Year
$80.92
$3.98
Revenue Next Year
$4.44
$22.72
P/E Ratio
$29.40
N/A
Revenue Growth
19.07
54.77
52 Week Low
$16.62
$12.00
52 Week High
$23.78
$26.16

Technical Indicators

Market Signals
Indicator
EBC
ADPT
Relative Strength Index (RSI) 44.19 61.22
Support Level $22.04 $23.92
Resistance Level $22.73 $26.16
Average True Range (ATR) 0.41 1.03
MACD -0.14 -0.07
Stochastic Oscillator 31.70 75.64

Price Performance

Historical Comparison
EBC
ADPT

About EBC Eastern Bankshares Inc.

Eastern Bankshares Inc is a commercial bank that caters its products and services to retail, commercial, and small business customers. Its diversified products and services include lending, deposit, wealth management, and insurance products. The company has one operating segment: Banking business, which offers a range of banking, lending, savings, and small business offerings, and its wealth management and trust operations.

About ADPT Adaptive Biotechnologies Corporation

Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.

Share on Social Networks: